Find a Product

BioMAP® Phenotypic Profiling & Screening Services

Overview of the BioMAP Platform

BioMAP is the broadest, most physiologically relevant method to quickly and robustly determine the efficacy, safety and mechanism of action (MOA) of candidate drug molecules to support their pipeline progression.

BioMAP Systems are composed of:
  • Over 60 human primary cell-based models of tissue and disease biology
  • Profiling with 100’s of clinically relevant protein biomarkers
  • Database of 4,500+ reference compounds and a suite of bioinformatics for in-depth prediction of safety and MOA

Request a Quote

BioMAP Diversity PLUS Icon

Unbiased Characterization

Test Agents Across a Broad Range of Human Disease Models with Diversity PLUS™

The Diversity PLUS panel comprised of 12 BioMAP systems is used to inform on the potency, selectivity, safety, mechanism of action and disease indication of a test agent. A profile of biomarker activity of each test agent is generated and compared against the BioMAP reference database and 19 consensus mechanism class profiles of well-characterized drugs.

Learn More

Model Complexity of Tumor Microenvironments

BioMAP Oncology Systems

The BioMAP Oncology Systems model the complexity of different tumor microenvironments (TME) by combining primary human stromal or vascular cells with immune cells and human tumor cell lines to mimic interactions and signaling pathways that occur during tumorigenesis.  Use Oncology Panels to gain insight into TME specific mechanism of action, efficacy and safety-related effects of test agents.

Learn More

Maximize the Impact of Your Compounds in Combination

Evaluate the Effect of Drug Combinations with BioMAP

The BioMAP Combo ELECT service allows statistical evaluation of drug combinations to determine additive or antagonistic differences between drug agents in a nominated disease model of interest. Each agent is analyzed individually, and then statistically compared against a combination array of the two serially diluted agents.  Use Combo ELECT to inform on the optimal dosing, potential synergy or adverse effects of different drug pairings.

Learn More

Model the Adaptive Immune Cell Microenvironment

Gain Insight into a Diverse Set of Target Classes Using the
T Cell/Autoimmune Panel

The T Cell Autoimmune panel models the adaptive immune cell microenvironment, as well as the individual T and B cell responses during different types of inflammation. Use the T Cell panel to gain insight into inflammation-related effects, indication guidance and combination feasibility for a diverse set of target classes.

Learn More


Model Fibrosis in Various Tissue Environments

Understand Tissue Remodeling with the BioMAP Fibrosis Panel

The BioMAP Fibrosis Panel contains systems modeling the tissue environments of the lung and kidney during the complex inflammatory and pro-fibrotic conditions that occur in fibrotic disease, wound healing and extracellular matrix remodeling.  Use the Fibrosis Panel to gain insight into fibrosis-related effects, compound ranking, indication guidance and combination feasibility for a diverse set of target classes.

Learn More

Clinically Relevant Toxicity Insights Before Entering the Clinic

BioMAP Tox Alert™ for Diversity PLUS

The BioMAP Tox Alert service helps you to identify potential mechanisms of toxicity before testing your drug in human patients.

Learn More

Create Your Own Customized BioMAP Panel

Flexibility to Choose any Individual or Combination of Available BioMAP Systems

Create a custom panel to focus on project goals anywhere from lead optimization to preclinical safety.

Learn More


BioMAP Resources

What is BioMAP?


Recommended Benchmarks


BioMAP® Systems for Investigative Toxicology Watch Webinar
Introduction to BioMAP®: Primary Human Cell Systems for Drug Discovery Watch Webinar
Leveraging Predictive Human Adaptive Immune Cell Models for Drug Discovery Watch Webinar

Application Specific Case Studies

Secondary Activity of an Adrenergic Receptor Antagonist Read Case Study
Economic Impact of BioMAP® Profiling Read Case Study
Explaining a Clinical Adverse Event Read Case Study
Differentiating p38MAPK Inhibitors Read Case Study